Evercore Cuts Cencora (NYSE:COR) Price Target to $420.00

Cencora (NYSE:COR) had its target price trimmed by Evercore from $440.00 to $420.00 in a research note published on Thursday morning, Marketbeat reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages have also recently commented on COR. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Wells Fargo & Company increased their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. TD Cowen lifted their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $394.75.

Cencora Stock Up 2.0%

NYSE COR opened at $359.15 on Thursday. Cencora has a 12 month low of $237.71 and a 12 month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.55 and a debt-to-equity ratio of 3.62. The stock has a market cap of $69.67 billion, a PE ratio of 43.17, a P/E/G ratio of 1.66 and a beta of 0.68. The stock’s 50 day moving average is $345.91 and its 200 day moving average is $326.15.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same period last year, the firm posted $3.73 EPS. The company’s revenue was up 5.5% on a year-over-year basis. Research analysts predict that Cencora will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 28.85%.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer directly owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,316 shares of company stock valued at $7,151,265. Company insiders own 0.38% of the company’s stock.

Hedge Funds Weigh In On Cencora

Hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Cencora during the second quarter valued at $695,215,000. Marshall Wace LLP lifted its holdings in Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after buying an additional 1,672,762 shares in the last quarter. Mizuho Markets Americas LLC boosted its position in Cencora by 116.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock valued at $66,506,000 after buying an additional 1,511,906 shares during the period. Artisan Partners Limited Partnership purchased a new stake in Cencora in the 2nd quarter valued at about $411,888,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after acquiring an additional 1,241,186 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.